Department of Anesthesiology & Critical care, University College of Medical Sciences & Guru Teg Bahadur hospital, Shahdara, Delhi 110095, India.
Department of Anesthesiology, Pain medicine & Critical care, All India Institute of Medical Sciences, New Delhi, India.
Pain Manag. 2024 Jun 2;14(5-6):273-281. doi: 10.1080/17581869.2024.2370758. Epub 2024 Jul 12.
Diabetic peripheral neuropathy (DPN) induces chronic neuropathic pain in diabetic patients. Current treatments like pregabalin and duloxetine offer limited efficacy. This study evaluates combining pregabalin and duloxetine versus pregabalin alone for DPN pain relief, and explores gene modulation ( and ) to understand neuropathic pain's molecular basis. Diabetic patients with DPN were randomized into groups receiving combination therapy or pregabalin alone for 4 weeks. Pain intensity, gene expression and quality of life were assessed. Combination therapy significantly reduced pain, improved quality of life and upregulated and genes compared with monotherapy. Pregabalin and duloxetine combination therapy in DPN led to mRNA upregulation and negative correlation of gene expression with pain scores. This combination therapy effectively reduced pain and improved quality of life. CTRI/2021/02/031068.
糖尿病周围神经病变（DPN）可导致糖尿病患者出现慢性神经性疼痛。目前的治疗方法，如普瑞巴林和度洛西汀，疗效有限。本研究评估了普瑞巴林联合度洛西汀与普瑞巴林单药治疗 DPN 疼痛的效果，并探讨了基因调节（和），以了解神经性疼痛的分子基础。将患有 DPN 的糖尿病患者随机分为联合治疗组或普瑞巴林单药治疗组，疗程均为 4 周。评估疼痛强度、基因表达和生活质量。与单药治疗相比，联合治疗显著减轻了疼痛，改善了生活质量，并上调了和基因。普瑞巴林和度洛西汀联合治疗 DPN 导致 mRNA 上调，与疼痛评分呈负相关。这种联合疗法能有效减轻疼痛，改善生活质量。CTRI/2021/02/031068。
